“…Zachary et al have reported a rise in HLA-Ab in six of seven sensitized subjects treated with ATG for acute rejection episodes, with no HLA-Ab increase in unsensitized recipients also treated similarly with ATG [3,15]. Furthermore, a cohort of T-cell flow crossmatch positive patients receiving ATG induction demonstrated significantly worse graft survival than nonsensitized controls [19]. Finally, it has been speculated that the decrease in T-cell burden, including reduction in regulatory T cells, is relevant to the incidence of humoral rejection reported after induction with Campath-1H and treatment with sirolimus monotherapy [20,21].…”